Developing novel therapies to reduce blindness.
Perfuse Therapeutics is developing a product to improve blood flow to the retina, the most metabolically demanding tissue in the human body.
Our goal is to reduce the incidence of blindness.
Despite current standard of care, glaucoma remains to be the leading cause of blindness and diabetic retinopathy is the leading cause of blindness in the working population in the world.
Leadership
We have assembled a team with remarkable and proven expertise in ocular drug discovery, drug delivery/formulation and development to advance our programs.
Science
Our product is a first-in-class endothelin antagonist which improves ocular blood flow and thereby addresses the underlying pathology in ocular diseases driven by ischemia. Our initial disease indications are glaucoma and diabetic retinopathy.
Investors
We have a strong syndicate of leading venture capital firms with unique expertise in the ophthalmology market.
Ocular Diseases: A Global Need
Glaucoma and Diabetic Retinopathy
Open angle glaucoma is a leading cause of blindness in people aged 60 years and older and affects approximately 57.5 million people worldwide.
There are approximately 103 million adults in the world with Diabetic Retinopathy (DR) and DR is a leading cause of blindness among working-age adults.
